LIMD2

Across TCGA pan-cancer cohorts, LIMD2 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of LIMD2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LIMD2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LIMD2 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

KIRC, HNSC, and STAD are the cancer types where LIMD2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LIMD2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+1.677	<.001	12	view →
HNSC	Male	III,IV	+1.306	<.001	10	view →
STAD	All	II,III,IV	+1.609	<.001	7	view →
KICH	All	II,III,IV	−1.248	<.001	7	view →
BLCA	Male	All	+1.670	.002	6	view →
UCEC	All	All	+0.961	<.001	6	view →
BRCA	All	All	+0.765	<.001	6	view →
CHOL	All	All	+1.826	<.001	3	view →
THCA	All	IV	+1.817	<.001	3	view →
ESCA	All	All	+1.703	<.001	2	view →
KIRP	All	All	+0.518	.033	2	view →
LUAD	All	All	+0.356	.026	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

LIMD2–KIRC

Open the KIRC breakdown →